deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03050216

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Acute Myeloid Leukemia
Interventions ALT-803
Updated 14 times since 2017 Last updated: Jul 14, 2023 Started: May 16, 2017 Primary completion: Dec 15, 2019 Completion: Dec 15, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03050216, this PHASE2 trial focuses on Acute Myeloid Leukemia and remains completed. Sponsored by Masonic Cancer Center, University of Minnesota, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Aug 2023 · 7 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Aug 2023 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Apr 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

  5. Mar 2019 — Mar 2020 [monthly]

    Suspended PHASE2

  6. Oct 2018 — Mar 2019 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  7. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  8. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations